Neutrophils in Oncolytic Virus Immunotherapy
Author Information
Author(s): Zhou Danya, Zhang Chenglin, Sun Jingyi, Yuan Ming
Primary Institution: The First Affiliated Hospital of Anhui Medical University
Hypothesis
What is the role of neutrophils in oncolytic virus therapy for cancer treatment?
Conclusion
Neutrophils play a dual role in oncolytic virus therapy, both enhancing antiviral responses and potentially inhibiting the efficacy of the therapy.
Supporting Evidence
- Neutrophils constitute approximately 50% to 70% of human peripheral blood leukocytes.
- Patients with low neutrophil-to-lymphocyte ratio before treatment had significantly longer overall survival.
- Neutrophils can phagocytize viruses and release antiviral peptides.
Takeaway
Neutrophils are important immune cells that help fight infections and can also affect cancer treatments using special viruses that target tumors.
Methodology
This review summarizes existing literature on the role of neutrophils in various oncolytic virus therapies.
Potential Biases
Potential bias due to the focus on neutrophils while other immune cells may also play significant roles.
Limitations
Limited research on the specific interactions between neutrophils and oncolytic viruses.
Participant Demographics
Patients receiving oncolytic virotherapy from 2000 to 2020.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website